Cervical cancer primary prevention

Jump to: navigation, search

Cervical cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cervical Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cervical Cancer During Pregnancy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cervical cancer primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cervical cancer primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cervical cancer primary prevention

CDC on Cervical cancer primary prevention

Cervical cancer primary prevention in the news

Blogs on Cervical cancer primary prevention

Directions to Hospitals Treating Cervical cancer

Risk calculators and risk factors for Cervical cancer primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.

Primary Prevention

Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. [1]
  • HPV vaccine also is recommended for following target population:
    • Young homosexual or bisexual men who have sex with men through age 26
    • HIV infected young adult who have weakened immune system through age 26
    • Young adults who are transgender through age 26

References

  1. Markowitz, L. E.; Unger, E. R.; Saraiya, M. (2009). "Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges". JNCI Journal of the National Cancer Institute. 101 (7): 439–440. doi:10.1093/jnci/djp044. ISSN 0027-8874.
  2. Grce M (November 2009). "Primary and secondary prevention of cervical cancer". Expert Rev. Mol. Diagn. 9 (8): 851–7. doi:10.1586/erm.09.64. PMID 19895230.

Linked-in.jpg